Anlon Healthcare Q2 PAT jumps 146 percent, revenue more than doubles YoY

Revenue Growth 20pctPat Growth 25pctRelated Party TransactionsNegative Operating CashflowResults View source PDF Explain this filing

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.0%Reaction day

₹14.31

prior close

₹14.80

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+2.2% vs market

Pharmaceuticals peers, median of 157sector-0.2%+2.2% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.3

15m

-0.7

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.0-0.3+2.2-0.2+2.2

Next day

-1.6+0.7-2.3+0.5-2.1

+0.2+0.6-0.4+0.6-0.4

-0.8+0.5-1.3+0.5-1.3

+4.8+1.1+3.7+0.2+4.6

+10.1+0.3+9.9-0.6+10.8

+9.3-0.2+9.5-1.1+10.4

15d

+10.0-2.2+12.2-2.1+12.1

-1.3-4.9+3.6-3.2+1.9

-5.0-7.5+2.5-5.9+1.0

-14.0-4.8-9.3-6.4-7.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anlon Healthcare Q2 FY26: revenue from operations at Rs 5,220 lakhs, up 116 percent YoY from Rs 2,417 lakhs. H1 revenue up 38 percent to Rs 8,550 lakhs. Q2 PAT surged 146 percent to Rs 637 lakhs; H1 PAT up 163 percent to Rs 932 lakhs. H1 EPS at Rs 3.07. Board also approved related party transactions disclosure and IPO fund utilisation status. Of Rs 12,103 lakhs raised via the September 2025 IPO, Rs 8,245 lakhs deployed with no deviation reported.

Likely market impact

Strong quarter with revenue and PAT more than doubling, signalling strong API momentum post-IPO. Operating cash flow remains negative, worth tracking.